SCHEMBL3134625

SCHEMBL3134625

CC(=O)[C@@H]1CCC(=O)N1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2132866 1.00
SCHEMBL8920712 1.00
SCHEMBL8426408 0.87 HDAC3 (0.36)
SCHEMBL2143334 0.87 HDAC3 (0.36)
SCHEMBL17995 0.85 HDAC3 (0.36)
SCHEMBL6664539 0.80
SCHEMBL14827812 0.80
Pidolic Acid SCHEMBL27686835 0.79 CAD (0.40)
Pidolic Acid SCHEMBL27686845 0.79 CAD (0.40)
Pidolic Acid SCHEMBL28073235 0.79 CAD (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115232177-B Chemical synthesis method of shigella dysenteriae 10 type O-antigen oligosaccharide 江南大学 2024-07-30 CN disclosed
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient YUYU PHARMA, INC. (KR) 2024-07-16 US disclosed
US-20240066027-A1 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2024-02-29 US disclosed
US-20240058455-A1 BIOORTHOGONAL LINKERS AND REACTIONS THE GENERAL HOSPITAL CORPORATION 2024-02-22 US disclosed
EP-4255904-A2 NOVEL PAR-2 INHIBITORS Domain Therapeutics (FR) 2023-10-11 EP disclosed
US-11760723-B2 Method of preparing a DON prodrug from L-pyroglutamic acid DRACEN PHARMACEUTICALS, INC. (US) 2023-09-19 US disclosed
US-20230265480-A1 METHOD FOR DETECTION OF MICROORGANISMS NEMIS TECH AG (CH) 2023-08-24 US disclosed
CN-111107848-B Pharmaceutical composition containing amide derivatives, and preparation method and application thereof 江苏豪森药业集团有限公司 2023-05-23 CN disclosed
WO-2022117882-A2 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2022-06-09 WO disclosed
US-20220144888-A1 PEPTIDE PURIFICATION METHOD USING SULFONATE COMPOUND NAGASE & CO., LTD. (JP) 2022-05-12 US disclosed
US-20080050336-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2008-02-28 US disclosed
US-7321063-B2 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-01-22 US disclosed
US-7321063-B2 Sulfonamide inhibitors of aspartyl protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-01-22 US disclosed
US-20070244158-A1 Piperdine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-18 US disclosed
US-20070244158-A1 Piperdine Compound and Process for Preparing the Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-18 US disclosed
US-20070208055-A1 ALTERNATIVE SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES THEREOF NOVARTIS AG (CH) 2007-09-06 US disclosed
US-20070167409-A1 Compounds and Methods for Treating Toll-Like Receptor 2-Related Diseases and Conditions EISAI CO., LTD. (JP) 2007-07-19 US disclosed
US-20070043015-A1 Phenyl pyrrolidine ether tachykinin receptor antagonists MERCK & CO., INC. (US) 2007-02-22 US disclosed
US-20070043015-A1 Phenyl pyrrolidine ether tachykinin receptor antagonists MERCK & CO., INC. (US) 2007-02-22 US disclosed
US-20050159469-A1 HIV protease inhibiting compounds ABBVIE INC. 2005-07-21 US disclosed